SOLICITATION NOTICE
R -- Services for the Clinical Translation Efforts of Cancer Nanotechnology
- Notice Date
- 5/6/2009
- Notice Type
- Modification/Amendment
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- RFQ-NCI-90083-MM
- Archive Date
- 5/22/2009
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen,, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
- Small Business Set-Aside
- Total Small Business
- Description
- The National Cancer Institute (NCI), Office of Technology and Industrial Relations, Office of Nanotechnology, plans to procure services for the clinical translation efforts of cancer nanotechnology initiatives. This is a combined synopsis/solicitation and will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), as supplemented with additional information included in this notice. This is a 100 percent small business set aside. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. RFQ-NCI-90083-MM includes all applicable provisions and clauses in effect through FAR FAC 2005-31 (March 2009) simplified procedures. The North American Industry Classification System Code is 541690 and the business size standard is $7.0M. Only one award will be made as a result of this solicitation. DESCRIPTION: CLIN-001: Services for the Clinical Translation Efforts of Cancer Nanotechnology Initiatives. STATEMENT OF WORK: The contractor shall provide the Office of Nanotechnology at the National Cancer Institute (NCI), Office of Technology & Industrial Relations support for the clinical translation efforts of Cancer Nanotechnology initiatives and cooperate with the NCI-Alliance in Cancer Nanotechnology (NCI-ACN), committed to identifying promising clinical candidates in the nano-product pipelines of several start-up companies. The contractor shall identify products of promise for accelerated clinical development through competitive due diligence of proprietary high value nano-technologies in the cancer therapeutic and diagnostic (imaging) space. The purpose of the project is to provide peripheral support services to enhance the operation of the NCI Alliance in Nanotechnology, encompassing the following responsibilities. The contractor shall provide recommendations and guidance regarding the activities of NCI’s nanotechnology initiative as it relates to the network of nanotechnology companies focused on developing engineered nanotechnologies as targeted cancer therapeutics and imaging agents. Background: The nanotechnology is capable of contributing to solutions of mission-critical problems in cancer research. One of the goals of the NCI Alliance for Nanotechnology in Cancer is to develop and utilize nanomaterials and nanoscale devices technologies within the cancer research. NCI’s ultimate goal is to implement the components of the Alliance and catalyze targeted discovery and development efforts that offer the greatest opportunity for advances in the near and medium terms and to lower the barriers for those advances to be handed off to the private sector for commercial development. The Alliance focuses on translational research and development work in the following six major challenge areas, where nanotechnology can have the biggest and fastest impact. The contractor shall handle the technical approach for all tasks associated with the Alliance fro Nanotechnology in Cancer. Project objectives: i) The contract will allow NCI to carry out the activities of NCI’s nanotechnology initiative in developing strategies towards translating engineered nanotechnologies to the clinic. The activities involve support and recommendations related to enhancing the operation of the NCI Alliance in Nanotechnology. ii) The contract will improve the operations related to maximal use of information and resources that allow research efforts to better assist with finding a cure for cancer. Contractor Requirements: a)Ph.D. in biology, genetics or M.D. with at least 7 years of experience after obtaining the degree. b)Demonstrated experience in working independently in providing recommendations related to nanotechnology for cancer treatment. c)Experience in analyzing complex data d)General knowledge of the field related to Cancer Nanotechnology. e)Excellent communication skills to collaborate effectively in a multi-disciplinary environment. Contractor shall have experience in: The contractor should have a Ph.D. in biology, genetics or M.D. and at least 7 years of post-graduate experience (including postdoctoral research), and 2 years of experience in program evaluation. The contractor should have demonstrated expertise in providing advice related to the strategies of identifying the nanotechnologies for clinical development. The contractor should have knowledge of nanotechnologies in the cancer therapeutic and diagnostic (imaging) space. Contractor personnel shall have capabilities and experiences in providing recommendations related to product pipeline and identification of nanotechnologies for clinical development. The contractor shall have relevant experience in project managerial and technical competence with the ability to use a variety of advanced and sophisticated tracking and reporting tools on one or more thematic/programmatic areas of focus. The contractor should have both oral and written communication skills necessary to collaborate effectively in a multidisciplinary environment. In addition, the contractor should be capable of synthesizing, integrating and organizing complex information into technical summary reports, and planning and evaluation documents. The contractor should have experience in development of databases and use of programs to support information, such as Access and Excel, should be demonstrated. Contractor shall use: The contractor shall use tracking and reporting databases using Microsoft excel to carry out the providing support for the technology developments within the Office of Technology and Industrial Relations, Nanotechnology program. Scope of work: The contractor shall provide recommendations and guidance relating to the network of nanotechnology companies. These include: i) assessment of the companies’ capabilities, ii) assessment of the companies’ competitive position, iii) preparation of effective status report, iv) development of effective communications among the investigator community and government program officers. The contractor shall resolve the complex issues specific to products expected to enter human clinical trials in next few years including data sharing, resource sharing and regulatory aspects of medical products. The contractor shall provide comprehensive reports with specific recommendations for activities. The contractor shall interface with related cancer research and technology development programs that represent useful components for research such as bioinformatics, mouse models of human cancer, clinical trials and preclinical development programs for high throughput genomic sequencing, and proteomics. Specific tasks to be performed are: i.Provide recommendations and guidance resulting from strategy meetings called by the Program Director of the NCI-ACN to understand the specific aims and goals of the initiative as it relates to the identification of nanotechnologies for clinical development at NCI each month. ii.Initiate dialog with key operatives within selected companies; get acquainted with the pipeline of targeted nanotechnology platforms for therapeutic and imaging applications designed specifically to diagnose and treat cancer (minimum 5, maximum 8 in the limited time frame). iii.Critically evaluate product pipeline and claims for products expected to enter human clinical trials in 2009-2010. iv.Evaluate the relative merits of nanotechnologies to prioritize offerings in the pipeline poised to deliver on the promise of targeted imaging agents or therapeutics for cancer and provide a written report. v. Provide recommendations and guidance to the NCI Project Officer for dialog between the nanotechnology Alliance Program Director and Centers of Nanotechnology Excellence (CCNEs) to propose collaborations leveraging core competencies at these centers to advance the entry of nanotechnologies into clinical development. vi.Generate and submit comprehensive reports with specific recommendations for follow through activities. vii.Identify additional promising nanotechnology companies supporting objectives of imaging and therapy in cancer fulfilling the program requirements. Carry out due diligence process (as described above) for such new candidates. Reporting schedule/Deliverables: Results will be discussed periodically with collaborators during individual or group meetings. Written reports and figures summarizing the findings will be submitted at a monthly basis. Period of Performance: Performance shall be for six months from date of award. BASIS FOR AWARD: Award will be made, subject to available funding and quoter responsibility, to that acceptable quote, the price or cost of which is not necessarily the lowest, but which is sufficiently more advantageous to the Government than the lowest offer so as to justify the payment of additional amounts, based on the evaluation criteria described in this section All evaluation factors, other than cost or price, when combined are significantly more important than cost or price. However, cost/price may become a critical factor in source selection in the event that two or more offerors are determined to be essentially equal following the evaluation of all factors other than cost or price. In any event, the Government reserves the right to make an award to that offeror whose response provides the best overall value to the Government. The Evaluation Process: The Government will award a contract resulting from this quotation to the responsible contractor whose quote conforming to the quotation will be the most advantageous to the Government, price and other factors considered. The following evaluation factors shall be used to evaluate the prospective contractors and are listed in order of importance. 1. Technical Approach (80%) 2. Past Performance (20%) 3. Price FORMAT AND INFORMATION FOR SUBMITTING A QUOTATION: Please submit ONE (1) original plus three (3) copies of entire quotation. Please mark original as “ORIGINAL” and copy as “COPY.” Please submit responses in TWO SEPARATELY BOUND VOLUMES VOLUME 1: CONTRACT AND PRICING DOCUMENTS •Signed SF1449 (page 1, blocks 12, 17a, 21, 23, 24, 30a, 30b and 30c and other pricing information). •Signed amendments (if applicable). •Representations and Certifications (Contractors must have valid certification/registration in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) in order to receive an award). Please provide a copy of each, the CCR and ORCA registrations. The Evaluation Criteria shall be applied in assessing quotations. The criteria are listed in descending order of importance. VOLUME 2: TECHNICAL FACTORS: 1.Technical Approach: (80 Points): The technical response should clearly and fully demonstrate the quoter’s full understanding of the capabilities, knowledge and experience, and personnel requirements, as stated in the statement of work. Failure to respond explicitly to each of the categories may result in the quoter’s offer/quotation being deemed technically unacceptable. 2.Past Performance: (20 Points) The Government will evaluate the offeror's past performance based on information obtained from references provided by the offeror, other relevant past performance information obtained from other sources known to the Government, and any information supplied by the offeror concerning problems encountered on the identified contracts and corrective action taken. The Government will assess the relative risks associated with each offeror. Performance risks are those associated with an offeror's likelihood of success in performing the acquisition requirements as indicated by that offeror's record of past performance. The Government will consider the currency and relevance of the information, source of the information, context of the data, and general trends in the offeror's performance. The lack of a performance record may result in an unknown performance risk assessment, which will neither be used to the advantage nor disadvantage of the offeror. The past performance subfactors are listed below in order of relative importance. These subfactors will be used to evaluate the quality of past performance. Past Performance Subfactors: •Record of conforming to specifications and to standards of good workmanship •Adherence to contract schedules, including the administrative aspects of performance •Reputation for reasonable and cooperative behavior and commitment to customer satisfaction •Business-like concern for the interest of the customer Past Performance Information: Quoters shall submit the following information as part of their response. •A minimum of three (3) references to include organization name, address, telephone number, a point of contact, a description of services provided, and the contract value 3.Price (Price will be evaluated separately but not scored). PROVISIONS AND CLAUSES: The following FAR provisions and clauses apply to this acquisition: FAR Clause 52.213-4 Terms and Conditions—Simplified Acquisitions FAR Clause 52.223-6 Drug-Free Workplace (May 2001) – IF APPLICABLE FAR 52.217-8 Option to Extend Services Full text copies of the representations and certifications for other cited provisions and clauses may be obtained on line at the NCI OA Internet website at http://amb.nci.nih.gov or from Melissa Marino, Contract Specialist at marinome@mail.nih.gov. OFFERORS: Offers must be submitted on an SF-1449, signed by an authorized representative and shall provide a copy of the valid certification registrations: (a) offeror’s Central Contractor Registration (CCR) and (b) Online Representations and Certifications Applications (ORCA). PLEASE NOTE: In order to receive an award, contractor must be registered in and have valid certifications in the Central Contractor Registration (CCR) (http://www.ccr.gov) and the Online Representations and Certifications Application (ORCA) (http://orca.bpn.gov) AND shall meet all the specifications stated above. Quotations must be received in the NCI-OA contracting office by 11:00 AM on May 7, 2009. Please refer to solicitation number RFQ-NCI-90083-MM on all correspondence. Faxed or electronic mail quotations will NOT be accepted.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=204cbc7374a8277b259f400eba58af52&tab=core&_cview=1)
- Record
- SN01810542-W 20090508/090506222213-204cbc7374a8277b259f400eba58af52 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |